D. Gossard

发表

Effects of low- and high-intensity home-based exercise training on functional capacity in healthy middle-aged men.

W. Haskell, C. Taylor, D. Ahn, 1986, The American journal of cardiology.

Limited usefulness of intermittent nitroglycerin patches in stable angina.

D. Gossard, M. Juneau, D. Waters, 1989, Journal of the American College of Cardiology.

Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan

A. Ducharme, J. Turgeon, R. Touyz, 2008, The Annals of pharmacotherapy.

Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.

J. Rouleau, A. Ducharme, R. Touyz, 2007, Journal of cardiac failure.

Early return to work after uncomplicated myocardial infarction. Results of a randomized trial.

H. Kraemer, C. Dennis, C. Taylor, 1988, JAMA.

Assessment of prescribed increases in physical activity: application of a new method for microprocessor analysis of heart rate.

H. Kraemer, W. Haskell, C. Taylor, 1986, The American journal of cardiology.

The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.

Janzen, A. M. Møller, D. Debanne, 1996, The Canadian journal of cardiology.

Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers

M. Grace, D. Gossard, A. Russell, 1993, Biopharmaceutics & drug disposition.

Plasma Levels of Nicotine and Safety of Smokers Wearing Transdermal Delivery Systems During Multiple Simultaneous Intake of Nicotine and During Exercise

D. Gossard, G. Caillé, J. Besner, 1997, Journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of a slow‐release formulation of diltiazem after the administration of a single and repeated doses to healthy volunteers

D. Gossard, P. du Souich, Y. Lacasse, 1994, Biopharmaceutics & drug disposition.

HEART-RATE CHANGES DURING NATURALLY-OCCURRING PANIC ATTACKS - AGREEMENT WITH SELF-REPORT

W. Roth, R. Maddock, J. Margraf, 1985 .

The effect of digoxin on mortality and morbidity in patients with heart failure.

E. J. Brown, Hack, D. M. Barr, 1997, The New England journal of medicine.

Ambulatory heart rate changes in patients with panic attacks.

W. Agras, W. Roth, R. Maddock, 1986, The American journal of psychiatry.

Early Return to Work After Uncomplicated Myocardial Infarction

H. Kraemer, D. Gossard, M. Juneau, 1988 .

Subungueal-Splinter Hemorrhage an Early Sign of Thromboangitis Obliterans

D. Gossard, A. Prat, J.G. Quenneville, 1981, Angiology.

LACTATE INFUSIONS AND PANIC ATTACKS - PSYCHOLOGICAL AND PHYSIOLOGICAL-CHANGES

W. Roth, R. Maddock, B. Kopell, 1984 .

Perceived self-efficacy and pain control: opioid and nonopioid mechanisms.

A. Bandura, A. O'Leary, C. Taylor, 1987, Journal of personality and social psychology.

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina

Gebhardt, D. DeMets, A. Capucci, 1998 .

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure.

D. M. Barr, D. F. Hughes, R. Collins, 1996, Controlled clinical trials.

Combination of Phenotype Assessments and CYP2C9‐VKORC1 Polymorphisms in the Determination of Warfarin Dose Requirements in Heavily Medicated Patients

J. Turgeon, M. Vanier, D. Gossard, 2008, Clinical pharmacology and therapeutics.

Long-term risk stratification with dipyridamole imaging.

S. Nattel, D. Gossard, J. Lette, 1995, American heart journal.

Lactate infusions and panic attacks: Do patients and controls respond differently?

W. Agras, W. Roth, R. Maddock, 1986, Psychiatry Research.

Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women.

D. Gossard, L. Roberts, M. Castles, 1997, Biopharmaceutics & drug disposition.